Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild

Cephalalgia

Volumn 24, Issue 11, 2004, Pages 918-924

  Klapper, Jack ^a   Lucas, C ^b   Rosjo O ^c   Charlesworth, B ^a  

^a Colorado Neurol and Headache Center ^*  (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c AstraZeneca ^*

Author keywords

Migraine; Optimizing treatment; Zolmitriptan

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SEDATIVE AGENT; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEAT SENSATION; HUMAN; HYPERESTHESIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; ODDS RATIO; OXAZOLIDINONES; PAIN; PROSPECTIVE STUDIES; TIME FACTORS; TRYPTAMINES;

EID: 8144223169     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00735.x     Document Type: Article

References (19)

1. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in Migraine. Drugs 1999; 58:347-74.
2. Goadsby PJ, Peatfield R. Zolmitriptan in the Acute Treatment of Migraine: an Overview. Rev Contemp Pharmacother 2000; 11:91-7.
3. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in Migraine. A Comparative Rev Pharmacol, Pharmacokinetics Efficacy Drugs 2000; 6:1259-87.
4. Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 2001; 15:583-7.
5. Tfelt-Hansen P, Block G, Dahlof C, Deiner HC, Ferrari MD, et al. Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia, 2000; 20:765-86.
6. International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38:173-83.
7. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers. Results of the spectrum study. Headache 2000; 40:792-7.
8. Cady RK, Sheftell F, Lipton RB, O'Quinn S, Jones M et al. Effect of Early Intervention with Sumatriptan on Migraine Pain: Retrospective Analyses of Data from Three Clinical Trials. Clin Ther 2000; 22:1035-48.
9. Winner P, Mannix L, McNeal S, O'Quinn S, Metz A. Treatment of migraine at the first sign of pain. prospective, double-blind, placebo-controlled, multicenter studies of sumatriptan 50 mg and 100 mg versus placebo. Neurology 2002; 58 Suppl 3:A415.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:19-21.
11. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53:988-94.
12. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997; 277:925-6.
13. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Färkkilä M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. A randomised, double-blind, placebo-controlled dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17:653-67.
14. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicentre, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49:1210-8.
15. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159:813-8.
16. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998; 50:1741-5.
17. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49:1219-25.
18. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for acute treatment of migraine. Neurology 1997; 49:1210-8.
19. Edmeads J, Johnson FN. The Adverse Event and Tolerability Profile of Zolmitriptan. Rev Contemp Pharmacother 2000; 11:119-32.